Skip to content
Wednesday, November 18, 2026
ClearVIP Group

Users Stopping Anti-Obesity Medications Regain Pounds Four Times Faster Than Those on Conventional Diets

Illustration of pharmaceutical injection and weighing machine
Obesity treatment often requires ongoing approaches.

A recent study suggests that individuals who discontinue new GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass far faster than those who stop traditional lifestyle plans.

Findings released in a major health publication demonstrates that while obese people often shed substantial amounts of their total mass while undergoing treatment, the mass returns at an average rate of nearly a kilo each month once they quit.

"Individuals using these medications should be cognizant of the potential of fast weight regain when the therapy ends," cautioned researcher Dr. Susan Jebb.

That rate of recovery suggests a return to original mass within about a year and a half.

Comparing Therapies

The analysis, which looked at 37 of trials involving over 9,000 of participants, compared the outcomes of these new drugs with other pills.

The team emphasize that individuals who shed pounds through diet and exercise generally have a less rapid weight regain—perhaps 0.1 kg a month—after stopping.

The Reason for the Quick Rebound

Nutrition scientists suggest the mechanism of the jabs explains the amplified regain.

These medications imitate a natural hormone called GLP-1, which helps regulate hunger.

"Sustained high doses of the hormone levels far above than the body's typical production may cause the body to produce less of its endogenous hormone, and could diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition expert.

"Discontinuation of this hormone supplement leads to appetite is unsuppressed, making excessive eating much more probable."

An Ongoing Disease?

Health authorities recommend the injections for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.

A number of clinicians contend that, considering the likelihood of weight regain, the therapy should be considered ongoing.

This opinion is reinforced by pharmaceutical companies, who state that the results "underscore the persistent character of excess weight," similar to managing conditions like diabetes.

Patient Accounts

Users who have discontinued the jabs describe a powerful return of hunger.

"It was like a trigger flipping and you become extremely hungry," recalled one woman.

This challenge is exacerbated if users have not developed sustainable lifestyle or habit changes during treatment.

Growing Adoption

Survey data suggest that millions of people in the UK have used weight-loss jabs in the past year, with desire remaining high.

  • Use is more common among women than males.
  • The 40s and 50s age group shows the highest level of interest.
  • A large proportion access the medications through private prescriptions rather than the NHS.

In conclusion, researchers stress that while GLP-1 drugs are effective tools for weight loss, they are not a standalone fix and long-term success likely depends on ongoing lifestyle support.

ML
Written by

Mark Lynn

Elena Vance is a seasoned business strategist with over 15 years of experience in corporate consulting and digital transformation.

ClearVIP Group

Type to search articles.